Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead abruptly parts ways with general counsel—Chutes & Ladders
Gilead abruptly parts ways with general counsel. Treg biotech turns new leadership leaf. Sensei says sayonara to C-suite.
Darren Incorvaia
,
Zoey Becker
Nov 21, 2025 8:30am
'Gilead wants us to rebuild': Why Galapagos can't go extinct
Nov 19, 2025 7:50am
Fierce Pharma
J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T
Nov 12, 2025 11:36am
Gilead settles on twice-yearly treatment partner for lenacapavir
Oct 30, 2025 6:37pm
Kite puts $1.64B on the line for Pregene's in vivo CAR-Ts
Oct 16, 2025 4:56pm
Evoq Therapeutics signs on with Sanofi in $500M partnership
Oct 16, 2025 10:25am
